Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 646  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Articlesmenu-bullet Search Instructions Online Submission Subscribe Etcetera Contact
 
  NAVIGATE Here 
  Search
 
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (706 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  References
 ::  Article Figures

 Article Access Statistics
    Viewed262    
    Printed9    
    Emailed0    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal


 


 
  Table of Contents     
CASE SNIPPET
Year : 2021  |  Volume : 67  |  Issue : 2  |  Page : 113-114

Strongyloides stercoralis hyperinfection in a patient with acute lymphoblastic leukemia


1 Department of Medical Oncology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India
2 Department of Pathology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India
3 Department of Surgical Oncology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha, India

Date of Submission15-Sep-2020
Date of Decision06-Oct-2020
Date of Acceptance05-Jan-2021
Date of Web Publication02-Apr-2021

Correspondence Address:
R Patnayak
Department of Pathology, Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jpgm.JPGM_1073_20

Rights and Permissions




How to cite this article:
Mishra S, Patnayak R, Panda S S, Jena A. Strongyloides stercoralis hyperinfection in a patient with acute lymphoblastic leukemia. J Postgrad Med 2021;67:113-4

How to cite this URL:
Mishra S, Patnayak R, Panda S S, Jena A. Strongyloides stercoralis hyperinfection in a patient with acute lymphoblastic leukemia. J Postgrad Med [serial online] 2021 [cited 2021 May 16];67:113-4. Available from: https://www.jpgmonline.com/text.asp?2021/67/2/113/313115




Strongyloides stercoralis is an intestinal nematode.[1],[2] Strongyloides infection is endemic in tropical, subtropical and sporadic in temperate areas.[3] Strongyloides larvae are identified in feces, body fluids, or in biopsy of involved tissues. It has a wide spectrum of manifestations varying from asymptomatic eosinophilia in the immunocompetent host to disseminated disease with septic shock in immunocompromised host.[1],[2]

In immunocompromised condition, the auto-infective cycle of Strongyloides can become amplified into a potentially fatal hyperinfection syndrome. Hyperinfection syndrome is characterized by increased numbers of infective filariform larvae in stool and sputum and clinical manifestations of the increased parasite burden and migration, like gastrointestinal bleeding and respiratory distress.[4]

An 18-years-old male was diagnosed with T-cell acute lymphoblastic leukemia (ALL) and attained remission after induction chemotherapy. He presented after the reinduction phase of chemotherapy, comprising of daily doses of oral dexamethasone 14 mg, with pain in the abdomen, vomiting, and bloating sensation. Initially, it was thought to be steroid-induced gastritis. He did not show any improvement with antacids or proton pump inhibitor. A peripheral blood smear examination revealed eosinophilia with 16% eosinophils. Absolute eosinophil count was 900/µl. Stool microscopy showed larvae of S. stercoralis. An upper gastrointestinal endoscopy showed grossly edematous and erythematous duodenal and jejunal mucosa studded with tiny pearly whitish nodules [Figure 1]a and [Figure 1]b. Duodenal biopsy revealed larval forms and eggs of S. stercoralis within the crypts [Figure 1]c. A combination of oral ivermectin 12 mg on days 1, 2, 15 and 16 along with albendazole 400 mg twice daily for 2 weeks was given following which the patient had prompt resolution of his symptoms. Seven days after starting treatment the stool microscopy did not show any larvae.
Figure 1: (a) Upper GI endoscopy showing duodenal mucosa studded with whitish pearly nodules due to parasitic infection (black arrow); (b) upper GI endoscopy showing duodenal mucosa with areas of mucosal hemorrhage (white arrow); (c) histopathology showing characteristic Strongyloides eggs and larvae within the crypts (black arrows). Also seen is an intense lymphoplasmacytic infiltrate (blue arrow) (hematoxylin and eosin ×400)

Click here to view


Autoinfection and hyperinfection with S. stercoralis is more common in immunocompromised hosts. Usually, these patients present with non-specific abdominal symptoms.[1],[3] Hyperinfection syndrome results from an increase in the concentration of circulating Strongyloides filariform larvae. Immunodeficiency states like hypogammaglobulinemia, acquired immunodeficiency syndrome, Cushing syndrome and patients receiving anti-cancer chemotherapy and corticosteroids can cause fatal hyperinfection.[2] Chemotherapy is supposed to play a role in promoting the maturation of Strongyloides larvae from a quiescent rhabditiform stage. Hyperinfection can lead to organ invasion due to large increase in worm burden.[3] A high degree of suspicion and necessary investigations can rule out strongyloidiasis in ALL patients with unexplained abdominal symptoms especially after induction and reinduction phases due to prolonged steroid exposure.[1]

A study by the University of Texas M. D. Anderson Cancer Center had opined that strongyloidiasis was uncommon in patients with cancer. It tends to remain localized in patients with solid-organ malignancies.[4] Very few reports are available in the literature regarding Strongyloides infection in leukemia patients.[3],[4] However, a study from Malaysia provided evidence of the occurrence of S. stercoralis infection among cancer patients.[5]

Strongyloides stercoralis hyperinfection may have been the unidentified cause of death in oncology centers in tropical regions in the absence of proper investigations. Successful management of hyperinfection syndrome requires early detection and initiation of therapy.[1] Ivermectin is the most effective therapy in strongyloidiasis.[6] In a randomized study, four doses of Ivermectin (on days 1, 2, 15, and 16) were no more efficacious than a single dose in non-disseminated strongyloidiasis. For hyperinfection and disseminated strongyloidiasis; especially in the immunocompromised; the higher dose schedule may be preferred in the absence of definite data.[7] Therefore, it is essential for cancer patients who are at risk for disseminated strongyloidiasis to have accurate diagnosis and appropriate treatment before and during immunosuppressive therapy.[4],[5]

Strongyloidiasis in acute leukemia is a mimicker in that the signs and symptoms are non-specific. High degree of suspicion and prompt treatment avoids unnecessary morbidity and delay in chemotherapy.

Declaration of patient consent

The authors certify that appropriate patient consent was obtained.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 :: References Top

1.
Nesheli HM, Moghaddam TG, Zahedpasha Y, Norouzi AR. Acute lymphoblastic leukemia with eosinophilia and Strongyloides stercoralis hyperinfection. Iran J Pediatr 2011;21:549-52.  Back to cited text no. 1
    
2.
Guerrero-Wooley R, Aranda-Aguirre E, Li W, Wilkin A, Palavecino E. Case report: Strongyloides stercoralis hyperinfection in a patient with chronic lymphocytic leukemia. Am J Trop Med Hyg 2017;97:1629-31.  Back to cited text no. 2
    
3.
McDonald HH, Moore M. Strongyloides stercoralis hyperinfection. N Engl J Med 2017;24:2376.  Back to cited text no. 3
    
4.
Safdar A, Malathum K, Rodriguez SJ, Husni R, Rolston KV. Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer 2004;100:1531-6.  Back to cited text no. 4
    
5.
Zueter AM, Mohamed Z, Abdullah AD, Mohamad N, Arifin N, Othman N, et al. Detection of Strongyloides stercoralis infection among cancer patients in a major hospital in Kelantan, Malaysia. Singapore Med J 2014;55:367-71.  Back to cited text no. 5
    
6.
Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: A case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health 2004;35:531-4.  Back to cited text no. 6
    
7.
Buonfrate D, Salas-Coronas J, Muñoz J, Maruri BT, Rodari P, Castelli F, et al. Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): A multicentre, open-label, phase 3, randomised controlled superiority trial. Lancet Infect Dis 2019;19:1181-90.  Back to cited text no. 7
    


    Figures

  [Figure 1]



 

Top
Print this article  Email this article
 
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow